In 1999, the Canadian Society of Nephrology (CSN) published clinical practice guidelines (CPG) for the treatment of patients with chronic kidney disease (CKD), 1,2 which included CPGs for the management of anemia coexistent with chronic renal failure. In 2003, responding to new evidence and emerging controversies, the CSN Executive Committee recognized the need to update these guidelines and establish new guidelines in areas of perceived clinical need. It was decided that guidelines for the management of hemodialysis, peritoneal dialysis, and non-dialysis CKD patients, as well as anemia management for all patients with CKD, would be developed or revised in a staggered manner over 3-5 years. The overriding objective was to establish national guidelines to improve the quality of health care delivered to patients with CKD in Canada.
Since the release of the original CSN anemia guidelines in 1999, several potentially practice-altering clinical trials have been published, with the most pertinent recent literature focusing on appropriate hemoglobin targets. [3] [4] [5] The aim of these revised CSN anemia guidelines is to define optimal management of anemia in CKD patients, where potential adverse effects are balanced against potential improvements in quality of life and avoidance of transfusion.
The guidelines that follow are intended to reflect the available evidence, as well as the human and financial resources in Canada at the time of this publication. Although the majority of proven therapies are currently funded in Canada, there are many therapies for which evidence of effectiveness on clinical outcomes is limited, or for which the only evidence is measured by non-clinical endpoints. These therapies are either not funded at all or funded only for select groups of patients. Health care professionals are often uncomfortable taking resource constraints and medication costs into account when making therapeutic decisions. However, in health care systems with constrained budgets, directing excessive resources toward expensive, marginally effective therapies limits the resources available to be used for other, effective therapies. As physicians are often in a good position to compare the benefits and risks of specific therapies, they should take an active role in deciding which therapies should be made available, by reimbursement, to Canadian patients. Thus, resource implications have been considered for each guideline presented in this document, though only after a thorough consideration of the safety and effectiveness of the therapy or test in question.
METHODS AND PROCESS FOR GUIDELINE DEVELOPMENT
Although content expertise was a prerequisite, geographic factors were also considered when choosing the CSN Anemia Work Group members. In addition to content expertise, it was necessary that the Work Group Chair have no personal financial or research relationships with the companies manufacturing products for the treatment of anemia. The Anemia Work Group was asked to utilize the extensive content and methodological review of the relevant literature obtained by the prior CSN guidelines committee 1 and the recent relevant publication from the Kidney Disease Outcomes Quality Initiative (KDOQI) Work Group. 6 This literature was supplemented by using the work group members' content expertise to identify new evidence as well as an Englishlanguage-focused literature search in nephrology and general medical journals. The Work Group assumed that new evidence of sufficient magnitude to warrant the revision of existing national guidelines would be discovered by using these two methods. Although this approach might be criticized for lack of methodological rigor, such an approach is pragmatic and has been utilized and advocated by others. 7, 8 The CSN anemia guidelines that follow are intended to rely on evidence and avoid opinion-based statements, where possible. Other similar work groups have made a distinction between clinical practice guidelines and clinical practice recommendations, with guidelines being provided when the work group thought that the evidence was sufficiently strong to make definitive statements about the appropriateness of After the CSN anemia guidelines were completed, Dr Culleton became an employee of Baxter Healthcare. Baxter Healthcare provided no funding for the guidelines, and provided no input into the drafting or final version of the guidelines.
clinical practice. 6 Alternatively, clinical practice recommendations were provided for statements based upon a lesser grade of evidence. The main reason for making this distinction was to highlight the areas where adherence to a guideline would be particularly likely to improve outcomes. Although this is a reasonable goal, it is unclear whether it was achieved, and distinguishing between guidelines and recommendations is very subjective.
Given the potentially arbitrary nature of the distinction between guidelines and recommendations, and to be consistent with previous CSN guidelines, we present only clinical practice guidelines. In all cases, guidelines are made only if the Work Group is confident that adherence would do more good than harm. The evidence in support of each guideline is graded using the scheme developed by the Canadian Hypertension Education Program 9 and used by the CSN Guidelines Committee in the past. 10 Where studies yield conflicting findings, or where lack of good-quality evidence makes it difficult to create clinical practice guidelines, we provide an overview of existing evidence, which we hope will guide management by practitioners. In these situations, specific research recommendations are also made.
The following anemia guidelines are organized into four sections: the first focuses on the evaluation of anemia in patients with CKD; the second deals with the assessment and management of iron deficiency in CKD patients; the third discusses the administration and monitoring of erythropoietinstimulating agents (ESAs) and the appropriate target hemoglobin; finally, the final section discusses the safety and effectiveness of supplemental therapies for anemia, and the assessment and management of patients with erythropoietin resistance.
The document focuses on the management of anemia in hemodialysis (HD-CKD) and peritoneal dialysis (PD-CKD) patients and non-dialysis patients with CKD stages 3-5 (ND-CKD). It does not discuss the management of anemia in children with CKD, nor in patients with functioning renal allografts. Where guidelines differ by CKD patient type, or are applicable to only one patient subgroup (for example, only those patients on hemodialysis), the relevant patient population is clearly stated.
The creation of these guidelines was facilitated by a faceto-face meeting at the 2006 CSN annual meeting in Quebec City, and by teleconferences as needed. The entire Work Group reviewed and modified the first draft of this document. The document was then distributed to all members of the CSN and relevant stakeholders, including the Kidney Foundation of Canada and provincial ministries of health, and was subsequently presented to the CSN membership at the CSN Annual meeting in May 2007. Comments from this external review were considered in detail, and responses to these comments can be viewed on the CSN website (www.csnscn.ca). The final revised draft of the anemia guidelines was completed in July 2007.
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